{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:46:11Z","timestamp":1793159171333,"version":"4.5.0"},"reference-count":19,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":2776,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objectives: According to one hypothesis, the popularity of levothyroxine (L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt;)\/liothyronine (L-T&amp;lt;sub&amp;gt;3&amp;lt;\/sub&amp;gt;) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt; monotherapy to L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt;\/L-T&amp;lt;sub&amp;gt;3&amp;lt;\/sub&amp;gt; combination therapy. Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt; monotherapy (without other explanations for the symptoms) were switched from L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt; monotherapy to L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt;\/ L-T&amp;lt;sub&amp;gt;3&amp;lt;\/sub&amp;gt; combination therapy at a ratio of approximately 17\/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants\u2019 reaction time as well as working memory by the California Computerized Assessment Package (CalCAP\u00ae). QoL was re-evaluated after 12 months. Results: Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p &amp;lt; 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change. Conclusion: Our study on hypothyroid patients switched from L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt; monotherapy to L-T&amp;lt;sub&amp;gt;4&amp;lt;\/sub&amp;gt;\/L-T&amp;lt;sub&amp;gt;3&amp;lt;\/sub&amp;gt; combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.<\/jats:p>","DOI":"10.1159\/000490383","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T17:03:41Z","timestamp":1531501421000},"page":"243-250","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":29,"title":["Levothyroxine\/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?"],"prefix":"10.1530","volume":"7","author":[{"given":"Luba\u00a0Freja","family":"Michaelsson","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe\u00a0Lerche\u00a0","family":"la\u00a0Cour","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarke\u00a0Borregaard","family":"Medici","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torquil","family":"Watt","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"},{"name":"2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Nygaard","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"},{"name":"2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"2026070712564168500_ref1","doi-asserted-by":"crossref","unstructured":"Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP: 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1: 55\u201371.","DOI":"10.1159\/000339444"},{"key":"2026070712564168500_ref2","doi-asserted-by":"crossref","unstructured":"Michaelsson LF, Medici BB, la Cour JL, Selmer C, Roder M, Perrild H, Knudsen N, Faber J, Nygaard B: Treating hypothyroidism with thyroxine\/triiodothyronine combination therapy in Denmark: following guidelines or following trends? Eur Thyroid J 2015; 4: 174\u2013180.","DOI":"10.1159\/000437262"},{"key":"2026070712564168500_ref3","doi-asserted-by":"crossref","unstructured":"Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P: Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur J Endocrinol 2014; 171: 593\u2013602.","DOI":"10.1530\/EJE-14-0481"},{"key":"2026070712564168500_ref4","doi-asserted-by":"crossref","unstructured":"Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U, Groenvold M, Rasmussen AK, Hegedus L, Bonnema SJ: Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS One 2016; 11:e0156925.","DOI":"10.1371\/journal.pone.0156925"},{"key":"2026070712564168500_ref5","doi-asserted-by":"crossref","unstructured":"Nygaard B, Jensen EW, Kvetny J, Jarlov A, Faber J: Effect of combination therapy with thyroxine (T4) and 3,5,3\u2032-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009; 161: 895\u2013902.","DOI":"10.1530\/EJE-09-0542"},{"key":"2026070712564168500_ref6","doi-asserted-by":"crossref","unstructured":"Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90: 2666\u20132674.","DOI":"10.1210\/jc.2004-2111"},{"key":"2026070712564168500_ref7","doi-asserted-by":"crossref","unstructured":"Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas SL, Dayan C: Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 2014; 174: 32\u201339.","DOI":"10.1001\/jamainternmed.2013.11312"},{"key":"2026070712564168500_ref8","doi-asserted-by":"crossref","unstructured":"Karmisholt J, Andersen S, Laurberg P: Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab 2011; 96:E99\u2013E103.","DOI":"10.1210\/jc.2010-1521"},{"key":"2026070712564168500_ref9","doi-asserted-by":"crossref","unstructured":"Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ, Feldt-Rasmussen U: Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol 2010; 162: 161\u2013167.","DOI":"10.1530\/EJE-09-0521"},{"key":"2026070712564168500_ref10","doi-asserted-by":"crossref","unstructured":"Watt T, Cramon P, Hegedus L, Bjorner JB, Bonnema SJ, Rasmussen AK, Feldt-Rasmussen U, Groenvold M: The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J Clin Endocrinol Metab 2014; 99: 3708\u20133717.","DOI":"10.1210\/jc.2014-1322"},{"key":"2026070712564168500_ref11","doi-asserted-by":"crossref","unstructured":"Watt T, Bjorner JB, Groenvold M, Cramon P, Winther KH, Hegedus L, Bonnema SJ, Rasmussen AK, Ware JE Jr, Feldt-Rasmussen U: Development of a short version of the thyroid-related patient-reported outcome ThyPRO. Thyroid 2015; 25: 1069\u20131079.","DOI":"10.1089\/thy.2015.0209"},{"key":"2026070712564168500_ref12","doi-asserted-by":"crossref","unstructured":"Rasmussen SL, Rejnmark L, Ebbehoj E, Feldt-Rasmussen U, Rasmussen AK, Bjorner JB, Watt T: High level of agreement between electronic and paper mode of administration of a thyroid-specific patient-reported outcome, ThyPRO. Eur Thyroid J 2016; 5: 65\u201372.","DOI":"10.1159\/000443609"},{"key":"2026070712564168500_ref13","doi-asserted-by":"crossref","unstructured":"Hoi-Hansen T, Pedersen-Bjergaard U, Andersen RD, Kristensen PL, Thomsen C, Kjaer T, Hogenhaven H, Smed A, Holst JJ, Dela F, Boomsma F, Thorsteinsson B: Cognitive performance, symptoms and counter-regulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity. J Renin Angiotensin Aldosterone Syst 2009; 10: 216\u2013229.","DOI":"10.1177\/1470320309343007"},{"key":"2026070712564168500_ref14","doi-asserted-by":"crossref","unstructured":"Cramon P, Bonnema SJ, Bjorner JB, Ekholm O, Feldt-Rasmussen U, Frendl DM, Groenvold M, Hegedus L, Rasmussen AK, Watt T: Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population. Thyroid 2015; 25: 284\u2013291.","DOI":"10.1089\/thy.2014.0433"},{"key":"2026070712564168500_ref15","doi-asserted-by":"crossref","unstructured":"Hoermann R, Midgley JEM, Larisch R, Dietrich JW: Recent advances in thyroid hormone regulation: toward a new paradigm for optimal diagnosis and treatment. Front Endocrinol 2017; 8: 364.","DOI":"10.3389\/fendo.2017.00364"},{"key":"2026070712564168500_ref16","doi-asserted-by":"crossref","unstructured":"Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM: Common variation in the &lt;italic&gt;DIO2&lt;\/italic&gt; gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94: 1623\u20131629.","DOI":"10.1210\/jc.2008-1301"},{"key":"2026070712564168500_ref17","unstructured":"Carle A, Laurberg P, Steffensen R, Faber J, Nygaard B: Combination of DIO2 and MCT10 gene polymorphisms predicts the preference for T4+T3 therapy in hypothyroidism \u2013 a blinded randomized clinical study (abstract). Eur Thyroid J 2016; 5(suppl 1): 65\u201366."},{"key":"2026070712564168500_ref18","doi-asserted-by":"crossref","unstructured":"Beecher HK: The powerful placebo. J Am Med Assoc 1955; 159: 1602\u20131606.","DOI":"10.1001\/jama.1955.02960340022006"},{"key":"2026070712564168500_ref19","doi-asserted-by":"crossref","unstructured":"Duntas LH, Wartofsky L: There is no \u2018universal fit\u2019: reflections on the use of L-triiodothyronine in the treatment of hypothyroidism. Metabolism 2016; 65: 428\u2013431.","DOI":"10.1016\/j.metabol.2015.11.005"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/490383","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/7\/5\/243\/34325\/etj490383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/7\/5\/243\/34325\/etj490383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:26:45Z","timestamp":1783445205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/7\/5\/243\/4644\/Levothyroxine-Liothyronine-Combination-Therapy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000490383","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,13]]}}}